Related Experiment Video
Updated: Nov 23, 2025
13:35
Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction
Published on: May 17, 2024
3.5K
Breast Implant-associated Anaplastic Large Cell Lymphoma
Shaikha Alotaibi1, Mehdi Hamadani2, Mubarak Al-Mansour3
1Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Clinical Lymphoma, Myeloma & Leukemia
|January 1, 2021
Summary
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare T-cell lymphoma linked to textured breast implants. Early diagnosis and surgical removal are crucial, with further treatment for advanced cases.
Area of Science:
- Oncology
- Hematology
- Immunology
Background:
- Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon lymphoproliferative disorder.
- It is primarily associated with textured breast implants, with diagnosis typically occurring in the mid-50s, 7-10 years post-implantation.
Purpose of the Study:
- To review the current understanding of BIA-ALCL, including its pathogenesis, diagnosis, and management.
- To highlight the classification of BIA-ALCL as a provisional entity by the World Health Organization in 2016.
Main Methods:
- Review of existing literature on BIA-ALCL.
- Histological and clinical comparison with other CD30-positive T-cell lymphomas.
- Discussion of diagnostic workup and treatment strategies.
Main Results:
- The exact incidence and prevalence of BIA-ALCL are not yet established.
- The pathogenesis remains unclear, with theories including immune response, bacterial infection, and genetic factors, none proven causal.
- BIA-ALCL is distinct from other ALCL subtypes.
Conclusions:
- BIA-ALCL requires thorough evaluation for diagnosis.
- Surgical resection is the primary treatment, with adjuvant radiotherapy and chemotherapy indicated for advanced stages.
